Glycaemic control and hypoglycaemia risk: comparison of insulin glargine 300 U/mL vs insulin glargine 100 U/mL

  • Yale JF & al.
  • Diabetes Metab
  • 23 Oct 2018

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This post hoc analysis suggests that compared with insulin glargine 100 U/mL (Gla-100), insulin glargine 300 U/mL (Gla-300) was associated with a reduced risk for nocturnal hypoglycaemia accompanied by comparable glycaemic improvement for people, aged ≥65 and

Why this matters

  • The risk for hypoglycaemia and its consequences is higher in older patients with T2DM; however, the safety and efficacy data of basal insulin therapy are limited in these population.

Study design

  • Meta-analysis included EDITION 1, 2 and 3 trials participants (≥65 and
  • Glycaemic efficacy, hypoglycaemia, body weight changes and insulin dosage and adverse events during 6 months’ treatment were evaluated.
  • Funding: None.

Key results

  • Of 2496 participants, 329 and 333 participants were ≥65 years old who received Gla-300 and Gla-100, respectively.
  • The least-squares (LS) difference in HbA1c change from baseline to month 6 was comparable for Gla-300 and Gla-100 in participants:
    • ≥65 years old; LS mean difference was 0.00% (0.00%; 95% CI, −0.14 to 0.15% [−1.53 to 1.64 mmol/mol]).
  • Lesser participants receiving Gla-300 vs Gla-100 experienced nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia:
    • ≥65 years old (relative risk [RR], 0.70; 95% CI, 0.57-0.85),
  • For both age groups, annualised rates of nocturnal confirmed or severe hypoglycaemia were lower with Gla-300 vs Gla-100.    

Limitations

  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit